Cargando…
Airway reversibility in asthma and phenotypes of Th2-biomarkers, lung function and disease control
BACKGROUND: High bronchodilator reversibility in adult asthma is associated with distinct clinical characteristics. In this study, we aim to make a comparison with T-helper 2 (Th2)-related biomarkers, lung function and asthma control between asthmatic patients with high airway reversibility (HR) and...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6307254/ https://www.ncbi.nlm.nih.gov/pubmed/30603020 http://dx.doi.org/10.1186/s13223-018-0315-0 |
_version_ | 1783382965539045376 |
---|---|
author | Wei, Jianghong Ma, Libing Wang, Jiying Xu, Qing Chen, Meixi Jiang, Ming Luo, Miao Wu, Jingjie She, Weiwei Chu, Shuyuan Mo, Biwen |
author_facet | Wei, Jianghong Ma, Libing Wang, Jiying Xu, Qing Chen, Meixi Jiang, Ming Luo, Miao Wu, Jingjie She, Weiwei Chu, Shuyuan Mo, Biwen |
author_sort | Wei, Jianghong |
collection | PubMed |
description | BACKGROUND: High bronchodilator reversibility in adult asthma is associated with distinct clinical characteristics. In this study, we aim to make a comparison with T-helper 2 (Th2)-related biomarkers, lung function and asthma control between asthmatic patients with high airway reversibility (HR) and low airway reversibility (LR). METHODS: Patients with asthma diagnosed by pulmonologist according to Global Initiative for Asthma guidelines were recruited from the outpatient department of our hospital from August 2014 to July 2017. Patients were divided into HR and LR subgroups based on their response to bronchodilators of lung function (HR = Δforced expiratory volume in one second (FEV1) postbronchodilator ≥ 20%). Blood eosinophil count and serum IgE level, which are biomarkers of T-helper (Th)-2 phenotypes, were detected for patients. Asthma Control Test (ACT) was used to assess asthma control after the first-month initial treatment. RESULTS: A total of 265 patients with asthma were followed 1 month after initial treatment. HR group shows a higher level of Th2-high biomarkers (blood eosinophil count (10^9/L): 0.49 ± 0.28 vs 0.36 ± 0.19, P < 0.01; IgE (ng/ml): 1306 ± 842 vs 413 ± 261, P < 0.01), lower baseline lung function (FEV1%pred: 51.91 ± 19.34% vs 60.42 ± 19.22%, P < 0.01; forced expiratory flow (FEF)25–75: 0.76 ± 0.37 vs 1.00 ± 0.67, P < 0.01; FEF25–75%pred: 21.15 ± 10.09% vs 29.06 ± 16.50%, P < 0.01), and better asthma control (ACT score: 22 ± 4 vs 20 ± 4, P = 0.01) than LR group. HR was associated with a decreased risk of uncontrolled asthma after the first-month initial treatment (adjusted OR: 0.12 [95% confidence intervals: 0.03–0.50]). CONCLUSIONS: HR is a physiologic indicator of lower lung function and severer small airway obstruction, and is more related with an increased level of Th2-biomarkers than LR. Moreover, HR may indicate controlled asthma after the first-month initial treatment. This finding may contribute to identification of asthma endotype. |
format | Online Article Text |
id | pubmed-6307254 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-63072542019-01-02 Airway reversibility in asthma and phenotypes of Th2-biomarkers, lung function and disease control Wei, Jianghong Ma, Libing Wang, Jiying Xu, Qing Chen, Meixi Jiang, Ming Luo, Miao Wu, Jingjie She, Weiwei Chu, Shuyuan Mo, Biwen Allergy Asthma Clin Immunol Research BACKGROUND: High bronchodilator reversibility in adult asthma is associated with distinct clinical characteristics. In this study, we aim to make a comparison with T-helper 2 (Th2)-related biomarkers, lung function and asthma control between asthmatic patients with high airway reversibility (HR) and low airway reversibility (LR). METHODS: Patients with asthma diagnosed by pulmonologist according to Global Initiative for Asthma guidelines were recruited from the outpatient department of our hospital from August 2014 to July 2017. Patients were divided into HR and LR subgroups based on their response to bronchodilators of lung function (HR = Δforced expiratory volume in one second (FEV1) postbronchodilator ≥ 20%). Blood eosinophil count and serum IgE level, which are biomarkers of T-helper (Th)-2 phenotypes, were detected for patients. Asthma Control Test (ACT) was used to assess asthma control after the first-month initial treatment. RESULTS: A total of 265 patients with asthma were followed 1 month after initial treatment. HR group shows a higher level of Th2-high biomarkers (blood eosinophil count (10^9/L): 0.49 ± 0.28 vs 0.36 ± 0.19, P < 0.01; IgE (ng/ml): 1306 ± 842 vs 413 ± 261, P < 0.01), lower baseline lung function (FEV1%pred: 51.91 ± 19.34% vs 60.42 ± 19.22%, P < 0.01; forced expiratory flow (FEF)25–75: 0.76 ± 0.37 vs 1.00 ± 0.67, P < 0.01; FEF25–75%pred: 21.15 ± 10.09% vs 29.06 ± 16.50%, P < 0.01), and better asthma control (ACT score: 22 ± 4 vs 20 ± 4, P = 0.01) than LR group. HR was associated with a decreased risk of uncontrolled asthma after the first-month initial treatment (adjusted OR: 0.12 [95% confidence intervals: 0.03–0.50]). CONCLUSIONS: HR is a physiologic indicator of lower lung function and severer small airway obstruction, and is more related with an increased level of Th2-biomarkers than LR. Moreover, HR may indicate controlled asthma after the first-month initial treatment. This finding may contribute to identification of asthma endotype. BioMed Central 2018-12-27 /pmc/articles/PMC6307254/ /pubmed/30603020 http://dx.doi.org/10.1186/s13223-018-0315-0 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Wei, Jianghong Ma, Libing Wang, Jiying Xu, Qing Chen, Meixi Jiang, Ming Luo, Miao Wu, Jingjie She, Weiwei Chu, Shuyuan Mo, Biwen Airway reversibility in asthma and phenotypes of Th2-biomarkers, lung function and disease control |
title | Airway reversibility in asthma and phenotypes of Th2-biomarkers, lung function and disease control |
title_full | Airway reversibility in asthma and phenotypes of Th2-biomarkers, lung function and disease control |
title_fullStr | Airway reversibility in asthma and phenotypes of Th2-biomarkers, lung function and disease control |
title_full_unstemmed | Airway reversibility in asthma and phenotypes of Th2-biomarkers, lung function and disease control |
title_short | Airway reversibility in asthma and phenotypes of Th2-biomarkers, lung function and disease control |
title_sort | airway reversibility in asthma and phenotypes of th2-biomarkers, lung function and disease control |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6307254/ https://www.ncbi.nlm.nih.gov/pubmed/30603020 http://dx.doi.org/10.1186/s13223-018-0315-0 |
work_keys_str_mv | AT weijianghong airwayreversibilityinasthmaandphenotypesofth2biomarkerslungfunctionanddiseasecontrol AT malibing airwayreversibilityinasthmaandphenotypesofth2biomarkerslungfunctionanddiseasecontrol AT wangjiying airwayreversibilityinasthmaandphenotypesofth2biomarkerslungfunctionanddiseasecontrol AT xuqing airwayreversibilityinasthmaandphenotypesofth2biomarkerslungfunctionanddiseasecontrol AT chenmeixi airwayreversibilityinasthmaandphenotypesofth2biomarkerslungfunctionanddiseasecontrol AT jiangming airwayreversibilityinasthmaandphenotypesofth2biomarkerslungfunctionanddiseasecontrol AT luomiao airwayreversibilityinasthmaandphenotypesofth2biomarkerslungfunctionanddiseasecontrol AT wujingjie airwayreversibilityinasthmaandphenotypesofth2biomarkerslungfunctionanddiseasecontrol AT sheweiwei airwayreversibilityinasthmaandphenotypesofth2biomarkerslungfunctionanddiseasecontrol AT chushuyuan airwayreversibilityinasthmaandphenotypesofth2biomarkerslungfunctionanddiseasecontrol AT mobiwen airwayreversibilityinasthmaandphenotypesofth2biomarkerslungfunctionanddiseasecontrol |